RHYTHM PHARMACEUTICALS, INC. (RYTM)

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Register to leave comments

  • News bot March 26, 2026, 1:16 p.m.

    📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical